Five Signs Your Hospital Is Overpaying for Perfusion

No one sets out to overpay for perfusion. It happens quietly, through contracts that renew on autopilot and a service line no one owns on the commercial side. The overpayment rarely announces itself — but it leaves signs. Here are five worth looking for, and what each one usually means.

1. Your contract auto-renews, and no one benchmarks it

If your perfusion agreement rolls over every year without anyone comparing its terms to the current market, you are pricing a specialized service against a market that may no longer exist. Auto-renewal is convenient by design — for the vendor. The absence of a benchmark is the single most common reason hospitals overpay.

2. You cannot produce a fully loaded cost per case

Ask your team what one perfusion case costs, all in — disposables, blood, equipment, and labor. If no one can answer quickly, that is the sign. You cannot know whether you are overpaying for a number you cannot see, and comparable programs performing the same operation routinely differ by a wide margin once that number is finally built.

3. Your staffing model has not changed as volume did

Perfusion coverage is often sized to assumptions made years ago. If your case volume has grown or shrunk while the coverage model stayed fixed, you are almost certainly paying for readiness that no longer matches demand — most expensively when premium or contract coverage fills a gap the volume never required.

4. Disposable pricing rises every year without challenge

Annual escalators are normal; unchallenged annual escalators are not. If oxygenators, custom tubing packs, and cannulae tick upward each renewal and no one re-prices them against the market, the compounding is real and quiet. These items frequently sit outside standard GPO contracts, so their pricing drifts the most.

5. The only performance report you get comes from the vendor

If the sole view of how your perfusion program is performing — clinically and commercially — is the one your vendor provides, you do not have oversight. You have marketing with a spreadsheet. No vendor reports itself overpriced or underperforming, and that is not a character flaw; it is the structure of the relationship.

What to do about it

None of these signs proves overpayment on its own — but two or three together is a strong signal that no one is independently watching. The fix is not to distrust your vendor; it is to have someone with clinical and commercial fluency, and no stake in the renewal, benchmark the program and read the contract. That independent read is exactly what a Perfusion Program Management Organization exists to provide — so administration can finally answer, with evidence, whether the price is fair.